Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157714 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Phase 1 study, sponsored by Prothena Biosciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02157714 is a Phase 1 study that has completed, run by Prothena Biosciences Limited. The registered enrollment target is 64 participants.
The verdict
NCT02157714, a Phase 1 study, has completed, sponsored by Prothena Biosciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
Interventions
- OTHER Placebo
- DRUG PRX002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157714
The ClinicalTrials.gov registry entry for NCT02157714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prothena Biosciences Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02157714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157714 about?
NCT02157714 is a clinical study titled "Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease". This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
What is the current status of trial NCT02157714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-06.
What interventions are being tested in trial NCT02157714?
The interventions under investigation include: Placebo (OTHER), PRX002 (DRUG).
Who is sponsoring clinical trial NCT02157714?
This trial is sponsored by Prothena Biosciences Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.